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ABSTRACT 
 
The authors present their experience over the last 20 years in limb salvage procedures of 
a consecutive series of 40 children un-der 10 years of age (range 2–10 years) with bone 
sarcomas. Nineteen were osteogenic sarcomas and 21 were Ewing sarcomas. Only one 
case, located in the distal phalanx of the toe, was treated by straight-forward 
amputation. Intercalary allografts and Cañadell’s technique were used to preserve joints 
whenever possible, and prosthesis or osteoarticular allografts were used when the joint 
surface was involved. Survival rate in this series was 75%. There were four local 
recurrences. At the last follow-up (mean 11.2 years, range 5–19 years postop), 90% of 
the patients preserved their limbs. Eighty percent of the authors’ results were excellent 
or good according to the Musculoskeletal Tumor Society Scale. Limb salvage is a real 
possibility even in young children with bone sarcomas. The age of the patient itself is 
not a contraindication for limb salvage. 
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INTRODUCTION 
 
Bone sarcomas are more frequently seen in children and adolescents.7,17–19 In the past, 
all these patients were treated by amputation, but the survival rates were very poor. 
Chemotherapy has changed this perspective in terms of survival and limb salvage 
possibilities. However, every institution has its own point of view regarding the 
possibilities of limb salvage in each case. Even within the same hospital, the criteria for 
limb salvage are not the same as time goes on. 
 
From a purely oncologic point of view, in almost every case of bone sarcoma it is 
possible to perform a limb salvage procedure, and in experienced institutions it does not 
therefore compromise patient survival when compared with amputation. From a 
functional point of view, however, there is no agreement among institutions. One of the 
most controversial points is limb salvage in children.5,21 Many believe that the best 
option in young children is amputation when the tumor is located in the lower limb, 
since it avoids growth-related problems. Several surgical techniques have been 
described for these cases, such as expandable prosthesis, bone lengthening, contralateral 
epiphysiodesis, extemporaneous lengthening by using allografts or prosthetic implants 
longer than the resected pieces, and so forth.3–6,8–16,20,22,24–26 All these techniques have 
potential complications. Another possibility is Van Ness rotationplasty, but it is really 
an intercalary amputation, and it is difficult to accept in many cases due to its cosmetic 
appearance.2 
 
We present our experience in the last 20 years in limb salvage procedures of a 
consecutive series of 40 young children with bone sarcomas. When possible, we 
preserved the growth plate near the tumor.20,22 We used in some cases bone lengthening 
by external fixation and/or contralateral epiphysiodesis to correct limb length 
discrepancies several years after tumor surgery.13,16,22 
 
 
METHODS 
 
Between 1980 and 1998 we treated in our institution 506 patients with bone 
sarcomas.7,17,19 Forty of them were children under 10 years of age (range 2–10 years). 
Table 1 shows the main data of the series. Nineteen were osteogenic sarcomas and 21 
were Ewing sarcomas. The most common location was the distal femur, followed by the 
proximal tibia. Most of them (33 cases) were IIb lesions. Seven patients had pulmonary 
metastases at diagnosis. Only one case, located at the distal phalanx of the toe, was 
treated by straightforward amputation. Three Ewing cases were not surgically treated. 
Therefore, all but four cases were treated by limb salvage procedures in addition to 
chemotherapy and/or radiotherapy, according to our protocols (Table 2). Van Ness 
rotationplasty was not performed in any case. 
 
The minimal follow-up was 5 years (except in cases of death), the maximum 19. The 
same medical team treated all patients, including surgeons, pediatric oncologists, and 
radiation oncologists. Follow-up was made every month during the first year (the year 
of chemotherapy), every 3 months the second year, every 6 months the third, fourth, and 
fifth years, and then every year. The function at last follow-up was measured according 
to the Musculoskeletal Tumor Society Scale (MSTS).1 In lower extremity locations, leg 
length discrepancy was particularly monitored and treated when necessary. Limb 
discrepancies in the upper limb did not require treatment. An inquiry was performed to 
assess the opinion of the patients about their surgical treatment at the last follow-up. 
 
 
RESULTS 
 
Mean follow-up for the living patients of the series was 11.4 years (range 5–19). 
Fourteen patients died between 6 months and 12 years after diagnosis. Four of them 
died of a cause independent from the disease (three due to toxicity of treatment and one 
due to a traffic accident 12 years after diagnosis, having no evidence of disease). 
Therefore, the survival rate in this series was 65% if we include those who died of an 
independent cause, or 75% if we do not. There were four local recurrences; three of 
them were treated by amputation. The other one could be removed, and a new allograft 
was implanted. Locations such as the proximal fibula, clavicle, or rib did not require 
reconstruction (five cases). For diaphyseal (and also for metaphyseal not involving the 
growth plate) tumors (17 cases), we used intercalary allografts. When the joint surface 
was resected, we employed prosthetic reconstructions (seven cases), osteoarticular 
allografts (five cases), or arthrodesis (one case). According to the MSTS scale, 
intercalary reconstruction had a better functional outcome compared with articular 
reconstructions (see Table 3). 
 
Infection was present in four cases, fracture of the allograft in six cases, and nonunion 
in three cases. Most of these complications could be solved with further operations (see 
Table 1). One patient required an amputation after several operations, including 
lengthening, due to complications from surgery (vascular involvement and bypass 
thromboses). 
 
Limb discrepancies in the upper extremity did not re-quire any surgical treatment, since 
the only problem is cosmetic. Depending on the possibilities in every case, lengthening 
was performed through the healthy or the affected bone (femur or tibia) or both. The 
criteria for doing a lengthening procedure included dissymmetry longer than 4 cm and 
at least 3 years free of disease.13,16,22 One patient required a Judet quadricepsplasty after 
correction of her whole discrepancy (9 cm) by lengthening through an allograft fracture 
(Fig. 1). Taking advantage of some other complication, we could also perform limb 
lengthening in two cases. Mean lengthening was 8.9 cm. The most problematic location 
regarding ultimate growth was the distal femur. One patient required 32 cm of 
lengthening in three surgical steps. 
 
The mean number of further major operations in the affected limb was 1.1 per patient 
(range 0–5). Other minor surgeries were performed, such as skin grafting, hemorrhage 
drainage, contralateral epiphysiodesis, and so forth. This number was higher in 
survivors. Therefore, the number of patients who did not require any further operation, 
including those who died, was 19. Only six survivors did not require a further operation. 
In several cases, more than one complication (eg, limb length discrepancy plus allograft 
fracture) could be resolved at the same surgical step. One patient who underwent 
amputation required a further operation for correcting a painful scar in the stump. 
 
All but one patient said they were very happy. Even those who underwent amputation 
said they did not regret having tried to preserve their limbs in the first operation; at 
least, then, they knew that both the medical team and their parents tried to do it. The 
only disappointed patient had several operations after resection of a distal femur 
osteosarcoma when he was 6 years old. As a result, he has very poor functionality, but 
he is now an adult and does not want to undergo an amputation. 
 
 
DISCUSSION 
 
This is a consecutive series of patients under 10 years of age treated by limb salvage 
procedures. No exclusion of patients with metastasis at diagnosis was made. A 20-year 
experience in a single institution is discussed. Only one straightforward amputation (in a 
case located at the distal phalanx of the toe) was performed. We have no experience 
with Van Ness rotationplasty. Ewing sarcoma is usually less frequent than osteogenic 
sarcoma,7 but it is the predominant type of bone sarcoma in young children. Ewing 
sarcoma is the most sensitive bone sarcoma to radiotherapy. This part of treatment can 
increase the possibilities of local control and survival, but it also has an important 
influence on the functional results. In addition, radiotherapy may cause radiation-
induced sarcomas. We did not see such a complication in this series. 
 
Even in distal locations such as the ankle, it is possible to preserve a very useful limb. 
Some authors advise an amputation in such a location, believing that a below-knee 
amputation will provide better functional results. One of our patients (patient 38) is a 
soccer player in his village team, 15 years after reconstruction with an intercalary graft 
of his distal fibula. He does not remember the operation (he was 4 years old) and has 
never had any functional restriction (Fig. 2). 
 
Consolidation of allografts is easier in children than in adults.23 Only three patients 
required autologous bone graft supplementation to achieve consolidation. After these 
operations, there were no pseudarthroses. 
 
Intercalary reconstructions had a better outcome in terms of function, lower number of 
complications, and so forth. This is why we perform epiphysiolysis before excision of 
selected cases of metaphyseal bone sarcomas in children.20,22 This technique is used 
when tumor does not invade the epiphysis. We started this technique in 1984, and we 
continue using it in young children and also in adolescents. It allows the preservation of 
most of the growth plate, together with the joint. Depending on several factors, such as 
the type of osteosynthesis used for reconstruction, these growth plates may continue 
growing. In any case, functional results are better when the joint can be preserved. 
 
The growth plates near the knee are the most important in terms of the ultimate growth 
of the lower limb. Chemotherapy usually inhibits growth in all growth plates, but once 
chemotherapy ends, the growth plates recover their potential of growing. In contrast, the 
damage of radiotherapy on the growth plate is permanent. Also, the age of the child is 
important to predict the final discrepancy: the younger the child, the longer the 
dissymmetry. Surgical resection of a growth plate may be necessary to remove the 
tumor. Reconstruction may also cause damage of another growth plate (eg, when using 
a knee prosthesis). Sometimes, however, the prosthesis can allow some growth if the 
prosthetic stem crossing the growth plate is thin enough. 
 
In some cases, to avoid or to diminish final discrepancy, we can use a reconstruction 
method longer than the resected piece. However, only 2 or 3 cm can be corrected in that 
way because of the risk of neurovascular damage. Chemotherapy can also play a role in 
the possibilities of neural damage. When the expected final discrepancy is not too long, 
contralateral epiphysiodesis may be the easiest way to treat the dissymmetry. A 
shortening osteotomy may be necessary if discrepancy is longer than 4 to 5 cm. 
 
Several kinds of growing prosthesis have been developed in recent years.8,11,24 The 
mechanisms of lengthening are now less invasive than they were before, and thus the 
risk of infection is now lower. The risk of fibrosis in these kinds of reconstruction is 
also important, and it can compromise joint motion. We have used most times fresh-
frozen allografts for reconstruction, since they have better biologic integration. 
However, they can also have complications such as nonunion, fracture, or infection. 
 
Bone lengthening is, in our opinion, the most physiologic way of correcting limb 
discrepancies in these patients.13,16,22 We applied it when discrepancy is greater than 4 
cm and the patient has been free of disease for at least 3 years. The timing of 
lengthening and callus formation is similar to those in other lengthening procedures 
because the patient is not receiving any cytostatic agents during the procedure. 
 
Both amputation and limb salvage have similar results in terms of survival and local 
control. In this series survival was found to be similar to overall series of bone 
sarcomas, as well as the risk of local recurrence. Limb salvage may have in young 
children a higher number of complications than amputation, but amputation cannot be 
converted into a limb salvage procedure; limb salvage, however, can be converted into 
an amputation if it fails. Future function is the only reason for choosing amputation or 
limb salvage in many cases, and many times it cannot be predicted. Even in long-term 
follow-up studies, there are no differences in terms of economic cost between the 
techniques.12 
 
Doctors must explain to parents the possibilities of preserving the limb in these cases. 
Patients and parents usually do not accept amputation, at least not as the first surgical 
treatment. Sometimes it may be better to amputate rather than to perform many 
surgeries to preserve the limb, but you cannot predict at the time of diagnosis what will 
happen in the future. Most of the patients come to our institution looking for a limb 
salvage procedure. In many cases, some other doctors had advised an amputation based 
on the age of the patient, the location, and the difficulties in reconstruction, and most of 
them are now very happy with their limbs. Fortunately, the predictions of those doctors 
were not fulfilled in most cases. Only four (10%) patients required a secondary 
amputation, while 90% preserved their limbs. This series shows that limb salvage is a 
real possibility even in young children with bone sarcomas. Age itself should not be the 
main cause for choosing an amputation in young children. 
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Patient Age/  Gender Location 
Size  
(cm) Histology
Tumoral
Necrosis Surgery 
Radiotherapy 
(rads) 
1 10 M Humerus 25 E.S. 100%*** — 4000
2 10 M Distal femur 20 O.S. >90% Intercalary —
3 10 F Arm 12 E.S. 100% — 4000
4 10 M Clavicle** 15 E.S. 100% Resection 5500
5 10 F Proximal humerus 15 O.S. >90% Prosthesis —
6 10 M Rib 15 E.S. >90% Resection 4000
7 10 F Fibula 20 E.S. >90% Resection 6200
8 10 M Humerus 13 E.S. 100% Intercalary 6200
9 10 M Prox. tibia 12 O.S. 70% Intercalary —
10 10 M Tibia 6 E.S. 100% Intercalary 6000
11 10 F Distal tibia 11 T.O. 20% Intercalary —
12 10 F Distal femur* 12 OS. >90% Prosthesis —
13 9 F Distal femur* 21 C.O. >90% Intercalary —
14 9 F Clavicle 15 E.S. 100% Resection —
15 9 M Prox. tibia 14 C.O. 40% Osteoarticular —
16 9 M Pelvis 10 E.S. 100% Intercalary —
17 9 M Foot phalanx 2,5 E.S. 100% Fing. amputat —
18 9 M Prox. femur 18 E.S. 100% Prosthesis 4600
19 9 F Distal tibia 20 OS. 60% Ankle arthrodesis —
20 9 F Distal femur 24 OS. 100% Intercalary —
21 9 F Dist. femur* 10 OS. >90% Prosthesis —
22 8 M Distal femur* 14 OS. >90% Osteoarticular ——
23 8 M Pelvis 5 E.S. 100% Intercalary 4500
24 8 M Distal tibia* 14 T.O. >90% Osteoarticular —
25 8 M Proximal tibia 14 E.S. 100% Intercalary 6000
26 8 M Distal radius 10 E.S. 100% Autograft 5800
27 8 M Proximal humerus 19 OS. >90% Prosthesis —
28 8 M Dist. femur 14 OS. 75% Osteoarticular —
29 8 M Prox. femur 15 E.S. 100% Prosthesis 4700
30 7 F Prox. tibia 16 E.S. 100% Intercalary 4600
31 7 F Prox femur* 10,5 OS. 100% Prosthesis —
32 7 M Scapula 10 E.S. 100% — 4500
33 6 M Distal femur 18 OS. 75% Intercalary —
34 6 F Distal tibia 13 T.O. 20% Osteoarticular —
35 6 F Dist. femur 12 E.S. >90% Intercalary 3700
36 5 M Prox. tibia 12 OS. 100% Intercalary —
37 4 F Rib 10 E.S. 100% Resection 3000
38 4 M Dist. fibula 8 E.S. 100% Intercalary —
39 3 F Distal femur 8 OS. >90% Intercalary —
40 2 M Distal tibia 12 E.S. 20% Intercalary —
 
 
 
 
 
 
 
Table 1. (Continued) 
 Length Discrepancy (cm)
Complications Treatment 
Pre Treatment Post 
Treatment    
of 
Metastasis 
Oncologic 
Status 
Follow
-up 
(years)
Elbow stiffness MUA — — — — D.O.D. 2 
Local 
recurrencence/  
infection 
Resection/  
amputation — — — — N.E.D. 9 
Fracture Osteosynthesis — — — — N.E.D. 12 
— — — — — Bone marrow 
autotransplant 
D.O.D. 5 
— — — — — — D.A.C. 3.5 
— — — — — — N.E.D. 19 
Peroneal n. palsy — — — — — D.O.D. 1.5 
— — — — — — D.O.D. 4 
Nonunion AGIF — — — — N.E.D. 12 
Infection Amputation 6 Lengthening + 
epiphysiodesis 
— — N.E.D. 15 
— — — — — — N.E.D. 7 
— — — — — Thoracotomy D.O.D. 1 
Nonunion Lengthening 10 Femur lengthening — Thoracotomy N.E.D. 16 
— — — — — — N.E.D. 7 
— — 5 Shoe 
supplementation 
5 — N.E.D. 6 
— — — — — — N.E.D. 5 
— — — — — — N.E.D. 8 
Dislocation Reduction 7 Femur lengthening — — N.E.D. 16 
Local recurrence Amputation — — — — N.E.D. 1.5 
Allograft fracture New allograft + 
lengthening 
9 Femur lengthening — — D.O.D. 11 
— — —  — — D.A.C. 0.5 
Allograft fracture New allograft + arthrodesis 24 
(2) Femural +      
(1) tibial length. 3 Thoracotomy N.E.D. 15 
— — — — — — N.E.D. 5 
 — — — — — Thoracotomy D.A.C. 4 
Allograft fracture New allograft 4 Femur lengthening — — N.E.D. 10 
— — — — — — D.O.D. 1 
— — — — — — D.O.D. 1.5 
Infection New allograft 10 Femur lengthening — — N.E.D. 14 
Loosening New prosthesis 10 — 10 — N.E.D. 14 
Nonunion Autografting 8 Tibial lengthening — — N.E.D. 15 
— — 8 Femur lengthening — (3) 
Thoracotomy 
D.O.D. 7 
— — — — — — D.A.C. 12 
Local recurrence + 
infection 
New allograft 35 (2) Femural + (1) 
tibial lengthening 
3  N.E.D. 17 
Allograft fracture AGIF — — — — N.E.D. 9 
— — — — — — D.O.D. 3 
Allograft fracture AGIF 6 Epiphysiodesis 2 — N.E.D. 10 
Thoracic 
deformity 
Plastic 
reconstruct. 
— — — — N.E.D. 16 
— — — — — — N.E.D. 16 
Local recurrence 
1. New 
allograft 
2. Amputation 
— — — — N.E.D. 9 
— — 6 Tibial lenghtening — — N.E.D. 6 
E.S., Ewing sarcoma; O.S., osteogenic sarcoma; T.O., telangiectatic osteosarcoma; C.O., 
chondroblastic osteosarcoma; MUA, mobilization under anesthetics; AGIF, Autologous grafting and 
internal fixation; D.O.D., dead of disease; N.E.D., no evidence of disease; D.A.C., dead from another 
cause. *Pulmonary metastasis at diagnosis; **pulmonary and bone metastasis at diagnosis; 
***according to post chemo and radiotherapy multiple biopsies. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Chemotherapeutic Protocol for Sarcomas in Pediatric Patients,                     
University of Navarra, Pamplona, Spain 
Osteosarcoma 
1.  Neoadjuvant chemotherapy 
Cisplatinum (CDDP) 40 mg/m2 intra-arterial (i.a.) days 1, 2, 3, 22, 23, 24, 43, 44, 45 
Adriamycin (ADR) 30 mg/m2 intravenously (i.v.) days 1, 2, 3, 22, 23, 24 
2.  Tumoral resection 
3.  Postoperative chemotherapy 
• Cycle A: CDDP 40 mg/m2 (i.a.) and ADR 30 mg/m2 (i.v.) for 3 days 
• Cycle B: (After 3 weeks) 
High-dose methotrexate (HDMTX) 12 g/m2 (i.v.) for 1 day 
Cyclophosphamide 500 mg/m2 (i.v.), actinomycin D 0.5 mg/m2 (i.v.) and 
bleomycin 10 mg/m2 (i.v.) for 1 day (within the same week as HDMTX) 
• Cycle A:  HDMTX 12 g/m2 (i.v.) for 1 day 
CDDP 40 mg/m2 (i.a.) and ADR 30 mg/m2 (i.v.) for 1 day (within the same 
week as HDMTX) 
Alternate cycles B and A until approximately 1 year after the beginning of treatment. 
Ewing Sarcoma 
Cycle A 
• Adriamycin (ADR) 20 mg/m2 intravenously (i.v.) and methotrexate (MTX) 12 mg/m2 
(i.v.), days 1, 2 and 3 
• Cyclophosphamide 1,200 mg/m2 (i.v.) and vincristine 1.5 mg/m2 on day 1 
Cycle B 
• Bleomycin 10 mg/m2 (i.v.) and actinomycin D 0.5 mg/m2 (i.v.) on days 21, 22, and 23 
• Cyclophosphamide 1,200 mg/m2 (i.v.) and vincristine 1.5 mg/m2 (i.v.) on day 21 
Notes 
• Alternate cycles A and B each 21 days until completion of 9–10 months of treatment. 
• In addition to chemotherapy the protocol includes local radiotherapy (in some cases) and 
tumor surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Functional Results in All the Cases Treated (MSTS Scale).      
The Two Cases Located in the Rib Were Excluded. 
Site of tumor Excellent Good Fair Poor 
Distal femur (9) 1 6 1 1 
Proximal tibia (6) 4 0 2 0 
Distal tibia (6) 4 0 2 0 
Proximal humerus (5) 2 1 2 0 
Proximal femur (3) 0 1 2 0 
Fibula (2) 1 0 1 0 
Clavicle (2) 1 1 0 0 
Pelvis (Illium) (2) 2 0 0 0 
Scapula (1) 1 0 0 0 
Distal radius (1) 0 1 0 0 
Phalanx of toe (1) 1 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. An 8-year-old girl diagnosed with osteosarcoma in the distal femur in 1989 
(A). She was treated by epiphysiolysis, resection of the tumor, and intercalary 
reconstruction (B). Five years later she had an allograft fracture (C). We took advantage 
of this event to correct both fracture and limb discrepancy (9 cm) (D–G). She also 
required a Judet quadricepsplasty (H–L), but she finished growth with an excellent limb 
function (M–O). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) A 4-year-old boy diagnosed with Ewing sarcoma in the distal fibula in 
1985. (B–D) Epiphysiolysis before excision of the tumor was performed. (E) 
Reconstruction was carried out with autologous contralateral nonvascularized fibula. No 
further operations were required. (F,G) Sixteen years later the patient remains 
absolutely asymptomatic and plays sports such as soccer. (H, I) Note the excellent 
function of the ankle joint. 
 
 
 
 
 
 
 
 
